Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Incyte (INCY – Research Report), reducing the price target to ...

Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte’s approved Opzelura. With several ...

Incyte says the firm it is acquiring has new drug candidates representing multibillion-dollar revenue opportunities.

Incyte to acquire Escient Pharmaceuticals and its pipeline of first-in-class oral MRGPR antagonists with the potential to ...

INCY stock results show that Incyte missed analyst estimates for earnings per share and missed on revenue for the first ...

Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its ...

Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88. INCY isn’t one of ...

Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 ...

Q1 Non-GAAP EPS of $0.64 misses by $0.19. Revenue of $880.89M (+8.9% Y/Y) misses by $43.75M. Jakafi (ruxolitinib) net product ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Revenue generated by the drugmaker in the first quarter from royalties was $126 million, up 9% from a year earlier. Incyte earns product royalty revenues from Novartis AG (NOVN.S) , opens new tab for ...

Incyte Corporation's underperformance belies its solid growth, profitability, and increased cash position. Click here for my ...